

Youla S Tsantrizos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5378215/publications.pdf>

Version: 2024-02-01

70
papers

3,197
citations

172386

29
h-index

155592

55
g-index

71
all docs

71
docs citations

71
times ranked

3016
citing authors

#	ARTICLE	IF	CITATIONS
1	An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. <i>Nature</i> , 2003, 426, 186-189.	13.7	881
2	Structure-Activity Study on a Novel Series of Macrocyclic Inhibitors of the Hepatitis C Virus NS3 Protease Leading to the Discovery of BILN 2061. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1605-1608.	2.9	189
3	Macrocyclic Inhibitors of the NS3 Protease as Potential Therapeutic Agents of Hepatitis C Virus Infection. <i>Angewandte Chemie - International Edition</i> , 2003, 42, 1356-1360.	7.2	166
4	Discovery of BI 224436, a Nucleoside Site Integrase Inhibitor (NCINI) of HIV-1. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 422-427.	1.3	139
5	Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans. <i>Organic Letters</i> , 2004, 6, 2901-2904.	2.4	104
6	Peptidomimetic Therapeutic Agents Targeting the Protease Enzyme of the Human Immunodeficiency Virus and Hepatitis C Virus. <i>Accounts of Chemical Research</i> , 2008, 41, 1252-1263.	7.6	104
7	Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3233-3244.	1.4	88
8	Solid-Phase Synthesis of Peptidomimetic Inhibitors for the Hepatitis C Virus NS3 Protease. <i>Journal of Organic Chemistry</i> , 2001, 66, 4743-4751.	1.7	64
9	Potent Inhibitors of the Hepatitis C Virus NS3 Protease: Design and Synthesis of Macrocyclic Substrate-Based β -Strand Mimics. <i>Journal of Organic Chemistry</i> , 2004, 69, 6185-6201.	1.7	59
10	Aristolochene Synthase. Elucidation of the Cryptic Germacrene A Synthase Activity Using the Anomalous Substrate Dihydrofarnesyl Diphosphate. <i>Journal of the American Chemical Society</i> , 1996, 118, 10037-10040.	6.6	54
11	Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2019, 54, 41-60.	2.3	52
12	Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 7144-7148.	7.2	50
13	Phytotoxic metabolites of <i>Phomopsis convolvulus</i> , a host-specific pathogen of field bindweed. <i>Canadian Journal of Chemistry</i> , 1992, 70, 2276-2284.	0.6	48
14	Olefin ring-closing metathesis as a powerful tool in drug discovery and development – potent macrocyclic inhibitors of the hepatitis C virus NS3 protease. <i>Journal of Organometallic Chemistry</i> , 2006, 691, 5163-5171.	0.8	48
15	RCM of Tripeptide Dienes Containing a Chiral Vinylcyclopropane Moiety: Impact of Different Ru-Based Catalysts on the Stereochemical Integrity of the Macrocyclic Products. <i>Journal of Organic Chemistry</i> , 2005, 70, 10765-10773.	1.7	47
16	Design and Synthesis of Active Site Inhibitors of the Human Farnesyl Pyrophosphate Synthase: Apoptosis and Inhibition of ERK Phosphorylation in Multiple Myeloma Cells. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3201-3215.	2.9	46
17	C-Nucleosides and related compounds. XV. The synthesis of D,L-2-epi-showdomycin and D,L-showdomycin. <i>Canadian Journal of Chemistry</i> , 1980, 58, 2024-2033.	0.6	44
18	Discovery of the First Thumb Pocket 1 NS5B Polymerase Inhibitor (BILB 1941) with Demonstrated Antiviral Activity in Patients Chronically Infected with Genotype 1 Hepatitis C Virus (HCV). <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7650-7666.	2.9	43

#	ARTICLE	IF	CITATIONS
19	Thienopyrimidine Bisphosphonate (ThPBP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase: Optimization and Characterization of the Mode of Inhibition. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7939-7950.	2.9	43
20	Modular Assembly of Purine-like Bisphosphonates as Inhibitors of HIV-1 Reverse Transcriptase. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7435-7449.	2.9	39
21	Human isoprenoid synthase enzymes as therapeutic targets. <i>Frontiers in Chemistry</i> , 2014, 2, 50.	1.8	37
22	Importance of Ligand Bioactive Conformation in the Discovery of Potent Indole-Diamide Inhibitors of the Hepatitis C Virus NS5B. <i>Journal of the American Chemical Society</i> , 2010, 132, 15204-15212.	6.6	36
23	Enzymatic Formation of Isochamigrene, a Novel Sesquiterpene, by Alteration of the Aspartate-Rich Region of Trichodiene Synthase. <i>Journal of the American Chemical Society</i> , 1996, 118, 8499-8500.	6.6	35
24	Peptaibol metabolites of <i>Tolypocladium geodes</i> . <i>Canadian Journal of Chemistry</i> , 1996, 74, 165-172.	0.6	34
25	Novel quinazolinones and enniatins from <i>Fusarium lateritium</i> Nees. <i>Canadian Journal of Chemistry</i> , 1993, 71, 1362-1367.	0.6	33
26	Unraveling the Prenylation "Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6904-6917.	2.9	33
27	Stereoselective Synthesis of a Thymine Derivative of (S)-2-Hydroxy-4-(2-aminophenyl)butanoic Acid. A Novel Building Block for the Synthesis of Aromatic Peptidic Nucleic Acid Oligomers I. <i>Journal of Organic Chemistry</i> , 1997, 62, 5451-5457.	1.7	32
28	Conformation-Based Restrictions and Scaffold Replacements in the Design of Hepatitis C Virus Polymerase Inhibitors: Discovery of Deleobuvir (BI 207127). <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1845-1854.	2.9	32
29	Human farnesyl pyrophosphate synthase is allosterically inhibited by its own product. <i>Nature Communications</i> , 2017, 8, 14132.	5.8	32
30	Discovery of thienopyrimidine-based inhibitors of the human farnesyl pyrophosphate synthase "Parallel synthesis of analogs via a trimethylsilyl ylidene intermediate. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2229-2240.	1.4	30
31	Multistage Screening Reveals Chameleon Ligands of the Human Farnesyl Pyrophosphate Synthase: Implications to Drug Discovery for Neurodegenerative Diseases. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5764-5776.	2.9	29
32	Antifungal antibiotics from <i>Pisolithus tinctorius</i> . <i>Phytochemistry</i> , 1991, 30, 1113-1118.	1.4	28
33	Structural Assignment of the Peptide Antibiotic LP237-F8, a Metabolite of <i>Tolypocladium geodes</i> . <i>Journal of Organic Chemistry</i> , 1996, 61, 2118-2121.	1.7	25
34	Title is missing!. <i>Angewandte Chemie</i> , 2003, 115, 1394-1398.	1.6	25
35	Isoprenoids and tau pathology in sporadic Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 65, 132-139.	1.5	24
36	Biosynthesis of the Hypotensive Metabolite Oudenone by <i>Oudemansiella radicata</i> . 1. Intact Incorporation of a Tetraketide Chain Elongation Intermediate. <i>Journal of Organic Chemistry</i> , 1995, 60, 6922-6929.	1.7	22

#	ARTICLE	IF	CITATIONS
37	Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme's active site closure. <i>BMC Structural Biology</i> , 2012, 12, 32.	2.3	21
38	Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2119-2134.	2.9	21
39	Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2585-2589.	1.0	19
40	Approaches towards the synthesis of a sulfur analog of ergosterol peroxide. <i>Canadian Journal of Chemistry</i> , 1992, 70, 158-164.	0.6	18
41	Backbone Modifications of Aromatic Peptide Nucleic Acid (APNA) Monomers and Their Hybridization Properties with DNA and RNA. <i>Journal of Organic Chemistry</i> , 2001, 66, 3372-3379.	1.7	18
42	Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 797-801.	1.3	18
43	Mutant lamin A links prophase to a p53 independent senescence program. <i>Cell Cycle</i> , 2015, 14, 2408-2421.	1.3	17
44	Studies on the Biosynthesis of the Fungal Metabolite Oudenone. 2. Synthesis and Enzymatic Cyclization of an β -Diketone, Open-Chain Precursor into Oudenone in Cultures of <i>Oudemansiella radicata</i> . <i>Journal of Organic Chemistry</i> , 1999, 64, 6609-6614.	1.7	16
45	Asymmetric Library Synthesis of P-Chiral t-Butyl-Substituted Secondary and Tertiary Phosphine Oxides. <i>Journal of Organic Chemistry</i> , 2019, 84, 7291-7302.	1.7	16
46	Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 711-716.	1.3	15
47	Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1117-1123.	1.0	15
48	Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active site "capping" phenyls. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 5583-5591.	1.4	14
49	Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5781-5786.	1.0	13
50	A Covalent Cysteine-Targeting Kinase Inhibitor of Ire1 Permits Allosteric Control of Endoribonuclease Activity. <i>ChemBioChem</i> , 2016, 17, 843-851.	1.3	13
51	Molecular tools that block maturation of the nuclear lamin A and decelerate cancer cell migration. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 5547-5554.	1.4	13
52	<i>P</i> -Chiral, <i>N</i> -phosphoryl sulfonamide Brønsted acids with an intramolecular hydrogen bond interaction that modulates organocatalysis. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 8690-8694.	1.5	13
53	TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection. <i>Current Opinion in Investigational Drugs</i> , 2009, 10, 871-81.	2.3	12
54	Determination of the absolute stereochemistry of the fungal metabolite (R)-2-(4-hydroxyphenyl)-2-hydroxyethanoic acid (pisolithin B). <i>Canadian Journal of Chemistry</i> , 1991, 69, 772-778.	0.6	11

#	ARTICLE	IF	CITATIONS
55	Hybridization Properties of Aromatic Peptide Nucleic Acids: A Novel Class of Oligonucleotide Analogues. <i>Organic Letters</i> , 2002, 4, 63-66.	2.4	11
56	Synthesis of novel analogs of aromatic peptide nucleic acids (APNAs) with modified conformational and electrostatic properties. <i>Tetrahedron</i> , 2004, 60, 2235-2246.	1.0	11
57	Synthesis of a novel 1,4-bridged calix[8]arene α -Host-cavity. <i>Tetrahedron Letters</i> , 1997, 38, 5411-5414.	0.7	10
58	Indole 5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase with nanomolar potency in cell-based subgenomic replicons (part 2): Central amino acid linker and right-hand-side SAR studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3664-3670.	1.0	10
59	Chirality-Driven Mode of Binding of β -Aminophosphonic Acid-Based Allosteric Inhibitors of the Human Farnesyl Pyrophosphate Synthase (hFPPS). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9691-9702.	2.9	10
60	Structure of human farnesyl pyrophosphate synthase in complex with an aminopyridine bisphosphonate and two molecules of inorganic phosphate. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2014, 70, 299-304.	0.4	9
61	A Highly Concise and Convergent Synthesis of HCV Polymerase Inhibitor Deleobuvir (BI 207127): Application of a One-Pot Borylation-Suzuki Coupling Reaction. <i>Organic Letters</i> , 2014, 16, 4558-4561.	2.4	9
62	β -Lactams. IX. The synthesis of 7- β -phenylacetamido-3-hydroxybenzo-[3,4]-O-2-isocephem, a weak antibacterial β -lactam antibiotic. <i>Canadian Journal of Chemistry</i> , 1981, 59, 2981-2987.	0.6	8
63	Pharmacophore requirements for HIV-1 reverse transcriptase inhibitors that selectively freeze the pre-translocated complex during the polymerization catalytic cycle. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 1713-1726.	1.4	8
64	Copper-boryl mediated transfer hydrogenation of N-sulfonyl imines using methanol as the hydrogen donor. <i>Tetrahedron</i> , 2021, 85, 132063.	1.0	6
65	Synthesis of Benzothiophene-Containing 10- and 11-Membered Cyclic Phostones. <i>European Journal of Organic Chemistry</i> , 2016, 2016, 3728-3736.	1.2	5
66	Crystallographic and thermodynamic characterization of phenylaminopyridine bisphosphonates binding to human farnesyl pyrophosphate synthase. <i>PLoS ONE</i> , 2017, 12, e0186447.	1.1	5
67	Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2471-2496.	2.9	5
68	Metal-Free Cycloetherification by in Situ Generated <i>P</i> -Stereogenic β -Diazanium Intermediates: A Convergent Synthesis of Enantiomerically Pure Dihydrobenzooxaphospholes. <i>Organic Letters</i> , 2017, 19, 894-897.	2.4	4
69	Bioactive metabolites of the genus <i>Phomopsis</i> . <i>Studies in Natural Products Chemistry</i> , 1995, 15, 341-359.	0.8	2
70	Rh(I)-catalyzed asymmetric transfer hydrogenation of β -enamidophosphonates to β -aminophosphonates. <i>Tetrahedron</i> , 2022, , 132908.	1.0	1